On the other hand, a recent analysis from the CALGB/SWOG 80405 trial found that high HER2 expressing mCRC (tumor gene expression above the median) had a longer PFS and OS than tumors with lower HER2 expression [59]. This evidence concerns the gene ERBB2 and neoplasm.